Bayer Swaps One Glyphosate Battle for Another After Landmark Court Ruling
Published on 07/05/2026 at 03:33 | Redaktion boerse-global.de
Less than a week after winning a historic Supreme Court decision that gutted thousands of Roundup lawsuits, Bayer has already moved to open a second front — this time against Chinese glyphosate producers. The rapid shift in strategy underscores just how many battles the German conglomerate must fight to defend its most controversial product.
The landmark ruling came on June 25, 2026, when the US Supreme Court voted 7-2 in favour of Monsanto (a Bayer subsidiary) in the case of Monsanto v. Durnell. The justices held that consumers cannot sue over the absence of a cancer warning on glyphosate packaging as long as the US Environmental Protection Agency does not require one. The decision overturned a $1.25 million award and, after nearly a decade of litigation that has cost Bayer more than $10 billion in legal fees, removed the legal foundation for the vast majority of outstanding Roundup claims.
Investors cheered the verdict with an immediate wave of buying. By Friday, shares had closed at €53.04, just 1.52% below the 52-week high of €53.86 that was reached on July 3. The stock has more than doubled over the past twelve months, rising 103.41%, and has surged 111.36% from its August 6, 2025 trough of €25.09. Over the past seven sessions alone, Bayer added 13.80%, while the one-month gain stood at 53.74%.
Yet the rally has come at a technical cost. The 14-day relative strength index has climbed to 85.1 — a level that screams "overbought" and historically precedes short-term profit-taking. The share price now sits 36.50% above its 50-day moving average of €38.86 and a staggering 42.91% above the 200-day average of €37.11. Annualised 30-day volatility of 63.19% underlines the frayed nerves beneath the surface.
Should investors sell immediately? Or is it worth buying Bayer?
A New Trade Offensive
Five days after the Supreme Court victory, Bayer took aim at a different adversary. On June 30, 2026, the company — through its Monsanto subsidiary and the newly formed Ruveon LLC — filed an antidumping and countervailing duty petition against Chinese glyphosate imports. The complaint, submitted to the US Department of Commerce and the International Trade Commission, alleges that Chinese producers are selling generic glyphosate in the United States at prices below fair market value, crushing the margins of the only remaining domestic manufacturer.
Bayer has already warned that revenue from glyphosate is expected to fall 2% to 6% in 2026 as cheap Chinese material weighs on pricing. Whether the petition will result in actual tariffs remains unclear; the US trade agencies must now decide whether to open an investigation. No timeline has been set.
The creation of Ruveon LLC, which began operations on July 1, is part of a broader effort to isolate the glyphosate business and manage the remaining legal risks more nimbly. Bayer also plans to hold its annual general meeting virtually in early August, followed by a key hearing in a class-action suit on August 19. That session will test whether the Supreme Court’s reasoning fully shields the company from future claims.
Bayer at a turning point? This analysis reveals what investors need to know now.
Pharma Offers a Side Catalyst
While trade and litigation dominate the headlines, the pharmaceutical pipeline is also stirring. The US Food and Drug Administration is currently reviewing the stroke-prevention drug Asundexian under an accelerated process, with results expected in the second half of 2026. Bayer has been pushing to boost margins in its pharma division by up to two percentage points annually through a sharper focus on specialty medicines.
What Comes Next
For traders, the overriding question is whether the rally can sustain itself. The psychological €50 mark — already tested and held — will be the first line of defence. A consolidation could see the stock retreat toward the 50-day moving average near €39. Conversely, if the antidumping petition gains traction and the FDA approves Asundexian, the re-rating of Bayer’s equity may still have room to run. The technical overhang is real, but the legal and commercial tailwinds are stronger than they have been in years.
Ad
Bayer Stock: New Analysis - 5 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
